



AAVBC

AMERICAN ACADEMY OF VALUE BASED CARE

Brain Cancer

Quick Reference Guide

2026

Table of Contents

1. CLINICAL SNAPSHOT	3
HCC/RAF V28 Mapping	3
2. RECOGNITION AND DIAGNOSIS	5
Medicare - Covered Diagnostic and Surveillance Workup	5
Atypical Presentation in Older Adults (>65)	7
Geriatric Risk Factors	8
Diagnostic Thresholds and Classification	10
Clues to Dig Deeper	11
Common Oversights	12
Key Differentials in Elderly	14
Comorbidity Screening	15
3. MEAT DOCUMENTATION AND ESSENTIALS	17
Clinical Documentation Elements	18
4. TREATMENT AND REFERRAL QUICK GUIDE	19
Therapy Escalation Criteria	20
NCCN v1.2026-Aligned Treatment by Subtype, Molecular Status, and Patient Profile	21
Non-Pharmacologic Care and Supportive Interventions	23
Medication Safety and Key Interactions	24
When to Refer	26
Follow-Up Timing	27
Comorbidity Management — Primary Care Role	29
Cost-Smart Options	30
Patient Education and Adherence	31
Quality Metrics Tie-In	32
5. CODING REMINDERS AND CASE EXAMPLES	33
Annual Clinical Review and Confirmation	35
Good Documentation — EHR Tips	35
Brief Case Examples	37
REFERENCES	38

1 CLINICAL SNAPSHOT

Definition: Malignant brain cancer includes **primary tumors** arising within the brain or central nervous system and **secondary/metastatic tumors** that spread to the brain from another primary site. Common primary malignant brain tumors include **glioblastoma, astrocytoma, oligodendroglioma, and other CNS malignancies**. Brain metastases most often arise from lung, breast, melanoma, kidney, and colorectal cancers. Final diagnosis depends on imaging, pathology, histology, and molecular classification.¹

ICD-10 Codes:

Primary brain malignancy is coded by anatomic site: **C71.0-C71.9**. Use the most specific location available from imaging or pathology, such as frontal lobe (**C71.1**), temporal lobe (**C71.2**), parietal lobe (**C71.3**), occipital lobe (**C71.4**), cerebellum (**C71.6**), brain stem (**C71.7**), overlapping sites (**C71.8**), or unspecified site (**C71.9**) only when location is not documented. Secondary/metastatic brain malignancy is coded **C79.31** and should be documented with the primary malignancy when known. **Z85.841** applies only after treatment is complete and there is no evidence of active disease, treatment, or surveillance.²

Prevalence and Burden: The American Cancer Society projects approximately **24,740 new cases** and **18,350 deaths** from malignant brain and spinal cord tumors in the United States in 2026, accounting for roughly 1.2% of all new cancer diagnoses.³ The overall **5-year relative survival rate is approximately 32.9%**, and the average age at diagnosis is **61 years**—about 9 in 10 cases occur in adults.³ **Glioblastoma**, the most common malignant primary brain tumor, is disproportionately a disease of older adults: patients **≥65 years** represent approximately one-third of all glioblastoma cases.^{4,5} GBD 2021 US data show the highest disability-adjusted life-year (DALY) rate in males aged 70–74 (**516.96 per 100,000; 95% UI 491.24–539.07**), confirming concentrated burden in the Medicare population.⁶ In a SEER analysis of **40,582 glioblastoma patients** (2000–2021), median overall survival for patients **>65 years** was **4 months** (95% CI 4–4) versus **19 months** (95% CI 18–20) for patients **≤65 years**; older age was associated with **HR 1.72** (95% CI 1.68–1.75; $p < 0.001$) for mortality.⁷

HCC/RAF V28 Mapping

ICD-10 CODE(S)	HCC CATEGORY (V28)	RAF (CNA)	DOCUMENTATION REQUIREMENT
C71.0-C71.9 Primary brain malignancy	HCC 20 — Lung and Other Severe Cancers²	1.136	Document active primary brain malignancy explicitly: “glioblastoma,” “malignant glioma,” “astrocytoma,” or “oligodendroglioma” — not only “mass” or “lesion.” Specify anatomic site , laterality when applicable, histologic confirmation, molecular markers, and active treatment/surveillance status ²

AAVBC Knowledge Hub Premium Content Access

Continue reading your guide
with an AAVBC subscription

[Subscribe Now](#)

Already a subscriber? [Sign in](#)

Limited offer

Basic Membership Free

Includes access to downloadable Quick Reference Guides, mailing list for industry updates/medical information, research toolkits, AAVBC events and so much more!

Cancel at any time